Dr. Leon Chen is the Founder and Managing Partner of Frontline BioVentures. In May, 2017, Frontline BioVentures (Frontline) and WuXi Healthcare Ventures (WuXi Ventures) merged to form 6 Dimensions Capital – one of the largest healthcare focused investment group with unique capability and extensive coverage across China and the US. Dr. Chen became 6 Dimensions Capital’s CEO. Before founding Frontline BioVentures in 2012, Dr. Chen was a Partner with Fidelity Growth Partners Asia, and a Managing Partner with BioVeda China. Since 2005, Dr. Chen has led a number of investments in the life science sector in China including CITIC Pharmaceuticals, Hile Biopharma, Hua Medicine, Innovent Biologics, Adagene, TenNor Therapeutics, MDDF, Coherent Biopharma, Yikon Genomics, Huazhou, Bio Kangtai and Neusoft Medical.
Dr. Chen was a management consultant and a business adviser to Pharmaceutical and Biotech companies; past affiliations include McKinsey & Company, Ernst & Young LLP.
Dr. Chen also worked as a research scientist at Schering-Plough in New Jersey. He was a member of the discovery team of “VYTORIN”/”ZETIA” – now a multibillion dollar drug.
He received a BS degree from Peking University, a Ph.D. degree with top honor from Catholic University of Louvain, and was a Post-Doc Fellow at the Massachusetts Institute of Technology. Dr. Chen holds 6 issued US Patents and co-authored the 14th and 15th Ernst & Young Biotechnology Report.